Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Dec 1;20(12):3531-3532.
doi: 10.4103/NRR.NRR-D-24-00934. Epub 2024 Nov 13.

Alzheimer's disease treatment landscape: current therapies and emerging mechanism-targeted approaches

Eleen Yang  1 , Khaled S Abd-Elrahman  1   2   3
Affiliations

Alzheimer's disease treatment landscape: current therapies and emerging mechanism-targeted approaches

Eleen Yang et al. Neural Regen Res. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mechanism of action of current and emerging drugs for Alzheimer’s disease. (a) Cholinesterase inhibitor binds to acetylcholinesterase and prevents the breakdown of acetylcholine (A), potentiating the activation of acetylcholine receptors (AChRs); (b) N-methyl-D-aspartate receptor (NMDAR) antagonist binds to NMDARs and block glutamate (G) activation of NDMARs to inhibit excitotoxicity; (c) anti-amyloid antibody binds to amyloid-β protein (Aβ) aggregates to mark for clearance and prevent further Aβ plaque aggregation; (d) γ-secretase inhibitor blocks γ-secretase from cleaving amyloid precursor protein (APP) into the Aβ42 that forms Aβ plaque; (e) γ-secretase modulator shifts the cleavage of APP into smaller pieces that are less likely to aggregate into Aβ plaque; (f) tau-targeted drugs reduce the formation of neurofibtillary tangles; (g) M1 muscarinic acetylcholine receptor (M1 mAChR) agonist activates the receptor to enhance memory and learning. Created with BioRender.com.
See this image and copyright information in PMC

References

    1. Abd-Elrahman KS, Sarasija S, Colson TLL, Ferguson SSG. A positive allosteric modulator for the muscarinic receptor (M1 mAChR) improves pathology and cognitive deficits in female APPswe/PSEN1ΔE9 mice. Br J Pharmacol. 2022;179:1769–1783. - PubMed
    1. Bubley A, Erofeev A, Gorelkin P, Beloglazkina E, Majouga A, Krasnovskaya O. Tacrine-based hybrids: past, present, and future. Int J Mol Sci. 2023;24:1717. - PMC - PubMed
    1. Cummings J, Lee G, Nahed P, Kambar MEZN, Zhong K, Fonseca J, Taghva K. Alzheimer’s disease drug development pipeline: 2022. Alzheimers Dement (N Y) 2022;8:e12295. - PMC - PubMed
    1. Hur JY. γ-Secretase in Alzheimer’s disease. Exp Mol Med. 2022;54:433–446. - PMC - PubMed
    1. Li DD, Zhang YH, Zhang W, Zhao P. Meta-analysis of randomized controlled trials on the efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease. Front Neurosci. 2019;13:472. - PMC - PubMed

LinkOut - more resources